Bayer's High Hopes For Huntington's Gene Therapy As Novartis’s Branaplam Stumbles
France Gives Thumbs-Up To Trial
When the German major bought AskBio a couple of years ago, one of its assets was a gene therapy for Huntington’s, a devastating disease that leads to complete physical and mental deterioration. That asset, BV-101, is about to enter the clinic.
